SCHEMBL3540303

SCHEMBL3540303

CC1CN(C)CCN1c1ccc2nc(-c3n[nH]c4c(-c5nc6ccccc6[nH]5)cccc34)[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.55
FLT1 P17948 10/20 0.55
ABL1 P00519 2/20 0.45
CDK2 P24941 3/20 0.41
CDK4 P11802 2/20 0.41
CCNA2 P20248 2/20 0.41
CCND1 P24385 2/20 0.41
CCND3 P30281 2/20 0.41
KDR P35968 5/20 0.40
ITK Q08881 2/20 0.40
PDPK1 O15530 2/20 0.40
FLT3 P36888 2/20 0.40
CDK1 P06493 2/20 0.40
RET P07949 2/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
CHUK O15111 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537422 0.95 FGFR1 (0.49) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL5866656 0.88 FGFR1 (0.52) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL5866794 0.88 FGFR1 (0.52) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3535306 0.86 FGFR1 (0.75) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3541759 0.84 FGFR1 (0.58) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3542396 0.84 FGFR1 (0.58) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL15868926 0.84 FGFR1 (0.58) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3541724 0.82 FGFR1 (0.44) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3540684 0.81 FGFR1 (0.66) FGFR1FLT1ABL1CDK2CDK4
SCHEMBL3540882 0.79 FGFR1 (0.52) FGFR1FLT1ABL1CDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.